Qiagen (NYSE:QGEN) Given Average Recommendation of “Moderate Buy” by Analysts

Qiagen (NYSE:QGEN) has earned an average rating of “Moderate Buy” from the ten ratings firms that are covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $51.15.

Several research analysts have commented on QGEN shares. Hsbc Global Res raised Qiagen to a “hold” rating in a research report on Thursday, October 17th. Jefferies Financial Group reiterated a “buy” rating and issued a $54.00 price target (up previously from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. Finally, HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research report on Thursday, October 17th.

Qiagen Stock Performance

Shares of QGEN stock opened at $45.40 on Friday. The stock’s 50-day moving average is $43.21 and its two-hundred day moving average is $43.71. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. Qiagen has a 1 year low of $39.03 and a 1 year high of $47.44. The firm has a market cap of $10.36 billion, a price-to-earnings ratio of 116.41, a PEG ratio of 3.57 and a beta of 0.35.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC boosted its holdings in Qiagen by 12.0% in the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after purchasing an additional 269 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Qiagen by 21.0% in the second quarter. Blue Trust Inc. now owns 7,891 shares of the company’s stock valued at $339,000 after buying an additional 1,369 shares in the last quarter. Raymond James & Associates grew its holdings in Qiagen by 12.7% during the second quarter. Raymond James & Associates now owns 542,453 shares of the company’s stock worth $22,289,000 after acquiring an additional 61,008 shares during the period. Mayfair Advisory Group LLC purchased a new position in Qiagen in the second quarter worth $268,000. Finally, Fifth Third Bancorp lifted its holdings in Qiagen by 9.4% in the second quarter. Fifth Third Bancorp now owns 76,592 shares of the company’s stock valued at $3,147,000 after acquiring an additional 6,573 shares during the period. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.